医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReproCELL Announced: Sales Commencement of “ReproNeuro MQ Medium”, a Cell Culture Kit Which Enables the Creation of High-Functioning Nerve Cells Derived from Human iPS Cells

2015年07月22日 PM10:00
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

This is a notice that we will on August 3rd commence sales of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells.

The “ReproNeuro” series which we have sold so far enables the creation of nerve cells from human iPS cells, and has been widely used by pharmaceutical companies during the drug development process for the evaluation of nerve cell toxicity. It has been highly rated for its ability to reduce the number of experiments previously required to be performed on animal subjects. At ReproCELL we have continued our research and development in order to bring these nerve cells closer to the ideal of being like those within a living human body.

With this new “ReproNeuro MQ Medium”, we have developed a specialist culture fluid for making nerve cells, and succeeded in increasing the electrical activity of nerve cells created from iPS cells. We expect this to distinguish our company`s superior nerve cell development, to lead to both an improvement in the reliability of and expansion in the utility of toxicity evaluations in the drug development process, and to contribute to a major reduction in the cost of the drug development process.

For more information, visit: https://www.reprocell.com/en/

View source version on businesswire.com: http://www.businesswire.com/news/home/20150722005541/en/

CONTACT

ReproCELL, Inc. (JASDAQ:4978)
Chikafumi Yokoyama, +81-45-475-3887
PhD
info_en@reprocell.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表